Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Related Keywords

United States , America , Awny Farajallah , Global Medical Affairs Oncology At Takeda , Takeda Pharmaceutical Company , Global Medical Affairs Oncology , North America , Middle East , Takeda , Mobocertinib , Exkivity , Fda , Lung , Nsclc , Non Small Cell Lung Cancer , Lung Cancer , Egfr , Egfr Exon 20 Insertion Mutation ,